Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

Last updated: June 23, 2025
Sponsor: BioGaia AB
Overall Status: Active - Recruiting

Phase

N/A

Condition

Colic

Treatment

L. reuteri

Placebo

Clinical Study ID

NCT06462651
CSUB0214 (CSUB0222)
  • Ages 3-12
  • All Genders

Study Summary

This is a double-blind, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying and fussing time.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Aged between 3-12 weeks at screening.

  2. Gestational age 37+0 weeks - 42+0 weeks at birth.

  3. Birth weight appropriate for gestational age (AGA - weight between 10th and 90thpercentile) or Large for Gestational Age (LGA - weight above the 90th percentile)determined using WHO Weight-for Age percentile guides.

  4. Parents/caregivers/legal guardians are >18 years.

  5. Exclusively or predominantly breastfed infants (> 50 % breast fed).

  6. Willing to maintain current feeding patterns (not change formula/not change ratio offormula:breast milk etc.).

  7. Readiness and the opportunity for parents/caregivers/legal guardians to fill out astudy diary, questionnaires.

  8. Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with aphysician, parents/caregivers/legal guardians must report that their infant hascried or fussed for 3 or more hours per day, during 3 or more days in the precedingweek). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24-hourperiod should show 3 or more hours of crying/fussing time.

  9. Parents/caregivers/legal guardians with ability to understand and comply with therequirements of the study, as judged by the Investigator.

  10. Parents/caregivers/legal guardians willing and able to give informed consent fortheir and their infant's participation in the study.

  11. The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 3 (Day 8),and Visit 4 (Day 22).

  12. Infant is considered healthy, in the opinion of the investigator following physicalexam.

Exclusion

Exclusion Criteria:

  1. Infants with severe gastroesophageal reflux (throwing up or spitting up more than ateaspoon of milk > 8 times daily, projectile, bilious or bloody emesis).

  2. Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container > 12x in breastfed and >5 in partially breastfed infants daily), or fever (38.0degrees), as reported by parents/caregivers/ legal guardians.

  3. Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cysticfibrosis, and those with liver disease.

  4. Infants with reported exposure to probiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.

  5. Infants with reported exposure to oral and/or systemic antibiotics in the 7 daysprior to Screening Visit (V1) and throughout the study period.

  6. Infants with reported exposure to medications, therapies, or products with the aimto relieve infantile colic including proton pump inhibitors in the 7 days prior toScreening Visit (V1) and throughout the study period.

Study Design

Total Participants: 50
Treatment Group(s): 2
Primary Treatment: L. reuteri
Phase:
Study Start date:
June 09, 2025
Estimated Completion Date:
August 30, 2026

Connect with a study center

  • University of Salento, University Hospital Vito Fazzi Lecce

    Lecce, LE 73100
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.